FY2028 EPS Estimate for C4 Therapeutics Lowered by Analyst

C4 Therapeutics, Inc. (NASDAQ:CCCC) – Brookline Capital Management decreased their FY2028 earnings estimates for C4 Therapeutics in a report issued on Thursday, November 6th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of $1.15 for the year, down from their prior forecast of $1.16. The consensus estimate for C4 Therapeutics’ current full-year earnings is ($1.52) per share. Brookline Capital Management also issued estimates for C4 Therapeutics’ FY2029 earnings at $12.57 EPS.

Several other brokerages have also issued reports on CCCC. Zacks Research lowered C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 22nd. Stephens restated an “overweight” rating and set a $6.00 price target on shares of C4 Therapeutics in a research report on Monday, September 22nd. Barclays raised their price objective on shares of C4 Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Monday, September 22nd. Guggenheim initiated coverage on shares of C4 Therapeutics in a research note on Wednesday, September 3rd. They issued a “buy” rating and a $8.00 target price on the stock. Finally, Wells Fargo & Company increased their target price on shares of C4 Therapeutics from $5.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, September 23rd. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.50.

C4 Therapeutics Trading Down 1.7%

Shares of CCCC opened at $2.34 on Monday. The stock has a 50 day moving average of $2.52 and a 200 day moving average of $2.08. The company has a market capitalization of $166.54 million, a price-to-earnings ratio of -1.40 and a beta of 2.95. C4 Therapeutics has a 12 month low of $1.09 and a 12 month high of $6.20.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.03. C4 Therapeutics had a negative net margin of 395.51% and a negative return on equity of 64.40%. The firm had revenue of $11.23 million during the quarter, compared to analyst estimates of $6.28 million.

Hedge Funds Weigh In On C4 Therapeutics

A number of large investors have recently modified their holdings of CCCC. Dynamic Technology Lab Private Ltd purchased a new stake in C4 Therapeutics in the 2nd quarter worth approximately $31,000. Savant Capital LLC bought a new position in shares of C4 Therapeutics in the second quarter worth $38,000. Catalyst Funds Management Pty Ltd purchased a new stake in shares of C4 Therapeutics in the second quarter worth $40,000. Crestwood Advisors Group LLC bought a new stake in C4 Therapeutics during the second quarter valued at $41,000. Finally, Brookstone Capital Management bought a new stake in C4 Therapeutics during the second quarter valued at $42,000. 78.81% of the stock is currently owned by institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.